These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alterations in the fibrinolytic system components during acute myocardial infarction. Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123 [TBL] [Abstract][Full Text] [Related]
3. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction. Soeki T; Tamura Y; Fukuda N; Ito S Jpn Circ J; 2000 Aug; 64(8):547-53. PubMed ID: 10952148 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction. Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503 [TBL] [Abstract][Full Text] [Related]
5. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044 [TBL] [Abstract][Full Text] [Related]
6. Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics. Pedersen OD; Gram J; Bagger H; Keller N; Jespersen J Coron Artery Dis; 1994 Jul; 5(7):617-23. PubMed ID: 7952424 [TBL] [Abstract][Full Text] [Related]
7. [A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease]. Chen ZY Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Jun; 21(3):163-4, 188. PubMed ID: 8243232 [TBL] [Abstract][Full Text] [Related]
9. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Pedersen OD; Gram J; Jeunemaitre X; Billaud E; Jespersen J Coron Artery Dis; 1997 May; 8(5):283-91. PubMed ID: 9285181 [TBL] [Abstract][Full Text] [Related]
10. Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction. Goto S; Kawai Y; Handa S; Abe S; Takahashi E; Watanabe K; Hori S; Ikeda Y Cardiology; 1993; 82(4):280-5. PubMed ID: 8402755 [TBL] [Abstract][Full Text] [Related]
11. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462 [TBL] [Abstract][Full Text] [Related]
12. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Chandler WL; Stratton JR Am J Clin Pathol; 1994 Aug; 102(2):248-52. PubMed ID: 8042597 [TBL] [Abstract][Full Text] [Related]
13. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors]. Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288 [TBL] [Abstract][Full Text] [Related]
14. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309 [TBL] [Abstract][Full Text] [Related]
15. Plasma plasminogen activator inhibitor-1, tissue plasminogen activator and serum lipoprotein(a) after reperfusion therapy in acute myocardial infarction: comparison between sequential and direct percutaneous transluminal coronary angioplasty. Hara M; Ito K; Nawata T; Tsunematsu Y; Shimoyama N; Maeda T; Sato Y; Saikawa T; Sakata T Cardiology; 1995; 86(5):407-10. PubMed ID: 7585744 [TBL] [Abstract][Full Text] [Related]
16. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Angleton P; Chandler WL; Schmer G Circulation; 1989 Jan; 79(1):101-6. PubMed ID: 2491971 [TBL] [Abstract][Full Text] [Related]